<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00192777</url>
  </required_header>
  <id_info>
    <org_study_id>BM-RT-Xeloda.CTIL</org_study_id>
    <nct_id>NCT00192777</nct_id>
  </id_info>
  <brief_title>Concurrent Xeloda and Radiotherapy for Bone Metastases</brief_title>
  <official_title>Concurrent Xeloda and Radiotherapy for Bone Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rambam Health Care Campus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rambam Health Care Campus</source>
  <brief_summary>
    <textblock>
      Hypothesis: Radiosensitization using Xeloda should improve the rate of complete pain relief.

      Primary Objective:

        -  To determine the frequency of pain relief for the proposed regimen.

      Secondary Objective(s):

        -  To determine the duration of pain relief and narcotic relief for the proposed regimen.

        -  To determine the frequency of narcotic relief for the proposed regimen.

        -  To determine the toxicity of concurrent UFT and radiotherapy in patients with bone
           metastases.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2004</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The frequency of pain relief for the proposed regimen, using a scale that takes into account the subjective feeling and the use of analgesics</measure>
    <time_frame>after 3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The duration of pain relief and narcotic relief for the proposed regimen after one year</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The frequency of narcotic relief for the proposed regimen after one year</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The toxicity of concurrent UFT and radiotherapy in patients with bone metastases after one year</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Solid Tumors</condition>
  <condition>Bone Metastases</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xeloda</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>External Beam Radiotherapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The patient must be 18 years of age or older.

          2. The patient must have epithelial malignancy.

          3. Radiographic evidence of bone metastasis is required. Acceptable studies include plain
             radiographs, radionuclide bone scans, computed tomography scans and magnetic resonance
             imaging.

          4. The patient must have pain that appears to be related to the radiographically
             documented metastasis.

          5. Patients must have an estimated life expectancy of 3 months or greater.

          6. Signed study-specific informed consent.

          7. Karnofsky performance status ï‚³ 40.

          8. Calculated creatinine clearance &gt; 50 ml/min
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kuten Abraham, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. of Oncology, Rambam Health Care Campus</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zvi Bernstein, MD</last_name>
    <phone>972 4 8541812</phone>
    <email>z_bernstein@rambam.health.gov.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rambam Health Care Campus</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zvi Bernstein, MD</last_name>
      <phone>972 4 8541812</phone>
      <email>z_bernstein@rambam.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Zvi Bernstein, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>September 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2005</study_first_posted>
  <last_update_submitted>October 5, 2007</last_update_submitted>
  <last_update_submitted_qc>October 5, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 8, 2007</last_update_posted>
  <keyword>Solid Tumors</keyword>
  <keyword>Bone Metastases</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>Xeloda</keyword>
  <keyword>Concurrent</keyword>
  <keyword>Radiosensitization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Bone Neoplasms</mesh_term>
    <mesh_term>Bone Marrow Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

